{"name":"Aclaris Therapeutics, Inc.","slug":"aclaris-therapeutics-inc","ticker":"","exchange":"","domain":"aclaristx.com","description":"","hq":"Malvern","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"oncology","drugs":[{"name":"A-101 40%","genericName":"A-101 40%","slug":"a-101-40","indication":"Other","status":"phase_1"},{"name":"A-101 Solution 40","genericName":"A-101 Solution 40","slug":"a-101-solution-40","indication":"Treatment of primary axillary hyperhidrosis","status":"phase_2"},{"name":"A-101 Topical Solution","genericName":"A-101 Topical Solution","slug":"a-101-topical-solution","indication":"Other","status":"marketed"},{"name":"A-101 Topical Solution 40%","genericName":"A-101 Topical Solution 40%","slug":"a-101-topical-solution-40","indication":"Treatment of primary axillary hyperhidrosis","status":"phase_2"},{"name":"ATI-502","genericName":"ATI-502","slug":"ati-502","indication":"Treatment of essential tremor","status":"phase_2"},{"name":"A-101 25%","genericName":"A-101 25%","slug":"a-101-25","indication":"Other","status":"phase_1"},{"name":"A-101 32.5%","genericName":"A-101 32.5%","slug":"a-101-32-5","indication":"Other","status":"phase_1"},{"name":"A-101 Solution","genericName":"A-101 Solution","slug":"a-101-solution","indication":"Seborrheic keratosis","status":"phase_3"},{"name":"A-101 Solution 45","genericName":"A-101 Solution 45","slug":"a-101-solution-45","indication":"Seborrheic keratosis","status":"phase_2"},{"name":"ATI-2138","genericName":"ATI-2138","slug":"ati-2138","indication":"Other","status":"phase_2"},{"name":"ATI-50002","genericName":"ATI-50002","slug":"ati-50002","indication":"Other","status":"phase_2"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"ATI-045","genericName":"ATI-045","slug":"ati-045","indication":"Moderate to severe atopic dermatitis","status":"phase_2"},{"name":"ATI-1777","genericName":"ATI-1777","slug":"ati-1777","indication":"Moderate to severe atopic dermatitis","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ATI-50002 topical solution","genericName":"ATI-50002 topical solution","slug":"ati-50002-topical-solution","indication":"Moderate to severe plaque psoriasis","status":"phase_2"}]}],"pipeline":[{"name":"A-101 40%","genericName":"A-101 40%","slug":"a-101-40","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"A-101 Solution 40","genericName":"A-101 Solution 40","slug":"a-101-solution-40","phase":"phase_2","mechanism":"A-101 Solution 40 is a topical solution used to treat hyperhidrosis.","indications":["Treatment of primary axillary hyperhidrosis"],"catalyst":""},{"name":"A-101 Topical Solution","genericName":"A-101 Topical Solution","slug":"a-101-topical-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"A-101 Topical Solution 40%","genericName":"A-101 Topical Solution 40%","slug":"a-101-topical-solution-40","phase":"phase_2","mechanism":"A-101 Topical Solution 40% is a topical solution used to treat hyperhidrosis.","indications":["Treatment of primary axillary hyperhidrosis"],"catalyst":""},{"name":"ATI-045","genericName":"ATI-045","slug":"ati-045","phase":"phase_2","mechanism":"ATI-045 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"ATI-1777","genericName":"ATI-1777","slug":"ati-1777","phase":"phase_2","mechanism":"ATI-1777 is a small molecule inhibitor of the JAK1 and JAK2 enzymes.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"ATI-502","genericName":"ATI-502","slug":"ati-502","phase":"phase_2","mechanism":"ATI-502 is a small molecule inhibitor of the serotonin receptor 5-HT2A.","indications":["Treatment of essential tremor"],"catalyst":""},{"name":"A-101 25%","genericName":"A-101 25%","slug":"a-101-25","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"A-101 32.5%","genericName":"A-101 32.5%","slug":"a-101-32-5","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"A-101 Solution","genericName":"A-101 Solution","slug":"a-101-solution","phase":"phase_3","mechanism":"A-101 is a topical solution that induces controlled necrosis of skin lesions through a proprietary mechanism.","indications":["Seborrheic keratosis","Common warts","Molluscum contagiosum"],"catalyst":""},{"name":"A-101 Solution 45","genericName":"A-101 Solution 45","slug":"a-101-solution-45","phase":"phase_2","mechanism":"A-101 Solution 45 is a topical keratolytic agent that chemically destroys skin lesions through controlled application of a caustic formulation.","indications":["Seborrheic keratosis","Actinic keratosis"],"catalyst":""},{"name":"ATI-2138","genericName":"ATI-2138","slug":"ati-2138","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ATI-50002","genericName":"ATI-50002","slug":"ati-50002","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ATI-50002 topical solution","genericName":"ATI-50002 topical solution","slug":"ati-50002-topical-solution","phase":"phase_2","mechanism":"ATI-50002 topical solution is a small molecule that targets the Janus kinase (JAK) pathway.","indications":["Moderate to severe plaque psoriasis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxNeUpIQXNZVy04VUptaGd1dDRMa1YwWjRHQTdsUXg2R1RuV0xlX2g5M1diZFpXNmszX1pIMjJ6SERvcmpaN1RlRmtBSWtITVVMVERMcU55UHVsZzUxTDRoVVhsZ3lpQmJVM2psYzRWZ0ZzbTF1YzJKcUM2WDRXNlJtQTZOb1NXSDJkUW9kZl9iUXE0SDNMX2htMklDd2dGNmlCbkN1c2ZpOVp2VlNzZzItS1ZBSUstclUyQ1IxcHVKYTkwUDQxRl94eVRLZnlRVEN2RGtBbnkyalNINEJucV96Vy1XTXpDWk9IdGdPdWVOVkZadGVvY21hYlRGLTdJSklnNGpuSmNKX0ZwcTJuSmJtbmJhQUtrTmthQkVINmtoWFVUWEU1ZmJZU1IwTklKX3N4Tm5rVGtuN1NMQWFqbFQ1YXh2dVZmWENTemthWm1IZw?oc=5","date":"2026-04-07","type":"regulatory","source":"Barchart.com","summary":"Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight -","headline":"Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeut","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxOMl9xSEpkeUExbFRIYy1ZbkV0a0ZmYVBGR24tOVNVekpqQXl4UE40UWRhZ0JoLTBDNy1GT1NlYmxTVGpfZlFIcFg3WmRfSXNmaDRJQXUyXzdxdlJtc0V4Vm1HOE9lUXBsWThqMldzNy1iZUZSWGV4NUp4V25kN1c3Y3N5VkhBek9tLThqS1I5LTVscVNXU1ZjODVhUkJJMVduUlpRY3FXX002Y0RlR3pCQ2RmTzlWSkExRDdkbW5kR2FJMURUZVRld3Z2X1hyMEJHczVxRmY2ZmNoTmZVWEVFYUJUOU45azh0OHgxVGg3bTVnT1B3cXJaQkN3X0JYU2xBREo0c0R3OXJ4cS10WUt4bmRXYWtsNmU4dW9uRHBwaUc?oc=5","date":"2026-03-11","type":"pipeline","source":"The Globe and Mail","summary":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Design Therapeutics (DSGN) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail","headline":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Design Therapeutics (DSGN) and Vertex Pharmaceuticals (VRTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxPVnZGYTBfR3o4czAtRFJXU1dwX190aXBvd3dCVUhxUnZXekRSeDR1TmN4ZkpHZWhVSlVBcWNVNXlXYmVQamUzWm9UR0hfY0pkaDNzV0NPdGV1aXFDREEzTGZTOUk0aEppbk9GUGs5b3R6MGdOOHR4djRLTkh2OW1Ub2t0dGh6SUV5VEctOFpOTzRHb05OSmRSVUQzRjhOOEZpZ3hfQ1hONzk0dm9xeEZqeTczSFBoWjllakRONGEzRzI1RDAxMlF6NmM3b0JYajJBWG1oU3dPczFZTkt6a3ZFeU5ER1pkZ0t6S21KVnUzVjhfRV9qRGJNb01HNkVUSVNIV0pmdEU4YU9fcGJBWmU0?oc=5","date":"2026-02-16","type":"pipeline","source":"PR Newswire","summary":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight - PR Newswire","headline":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | Delve","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-03","type":"pipeline","source":"simplywall.st","summary":"There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump - simplywall.st","headline":"There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-26","type":"pipeline","source":"simplywall.st","summary":"Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) high institutional ownership speaks for itself as stock continues to impress, up 72% over last week - simplywall.st","headline":"Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) high institutional ownership speaks for itself as stock continues to impress,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNTjZhV2l5SUJWbWR1MFFFZ2RoYmQtZmNDZUlCbVY4Tk85d2xUWE1TWm03RDA5OExWUnBoME9QS2ZmTHBvWWZXWmgxaUVYSHRwaHFmc2NBNUgyWTk5WnM4UDBNNnI5bDVGQmJKckhXM3NiRXFvMkVBYzFWTHZtRTVHY0diUTZqelFh?oc=5","date":"2025-07-15","type":"trial","source":"Yahoo Finance","summary":"Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases - Yahoo Finance","headline":"Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE1JQlZyOElTXy1zeDdtTTVrdE1XSU9lSV8yM1d0SFhRM3ZCaXVZanpITUk1cVowMVFTU2FnTU0tMFdibHdLV280ZjVYZmJWa243QV9yQQ?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"FPHAF Stock Price, News & Analysis - Stock Titan","headline":"FPHAF Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5DTHNFbTBNbi0zTW9acV9RczZfVUVSa2U5dnRKYzlUN21rZjFzUlRHZnBFS3o3OTEwNFllZmhGTWJDYk9ORWRyVVRrcF9KeFpqZlpDMkFxaV9WOU80endMQkZsZ2VqS090Tm9zUXlndDBSamRMcVlvU1Vn?oc=5","date":"2024-11-19","type":"pipeline","source":"Pharmaceutical Technology","summary":"Aclaris Therapeutics secures global rights to Biosion’s antibodies - Pharmaceutical Technology","headline":"Aclaris Therapeutics secures global rights to Biosion’s antibodies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNVElyc3ZWeGVudjhVaDhmN3g3c0JoMU85WHR0bDJIVUJVc1VzeDRZRGFleFRoVElzQUxGNVNVSkR0NnUxZkdaUXFHLVBYUU5KNVk2X215WFBwZXRoX1hKUXZTUHVodnYwa2xjOWJaQ1ZsUlRUbGZIVlRQQXdHcEt2ZllXY0lPZHlrdnJvbVg0MGt4LVJNa2JGSllNRmNJcXBvcVlROUx3NFppZDVVRzM3aGY2MU42eGJuZjRpLS1sREJiZDlxTmhfamdDYS11bm9TNldpNnNKU1dBTWNIX0dxZC1iR0c?oc=5","date":"2024-11-19","type":"deal","source":"BioPharma APAC","summary":"Biosion Secures $40M Upfront in Licensing Deal with Aclaris Therapeutics, with Milestones Exceeding $900M - BioPharma APAC","headline":"Biosion Secures $40M Upfront in Licensing Deal with Aclaris Therapeutics, with Milestones Exceeding $900M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxQbWMzRHJHTDhRZGJ6T1ZxZFBBa3lFR093c01BWEdXaDBTM1ZvcjhiN0lmMUNXSnBBclUzRkk5aXRrdDlrNFpqQVJWemd6M2ZvWjdYNmtlSVMzMHUyRjE5aEt3eTdOU2huZ2QwVnA3YkFCSnVEeEFXUi1vUmZLYm8yS1lkT3BLcjRFejFLcGstSGlSdGFIWkJwVzVrUnVTcmlkQktUNFphdVBFeEN6d1VWWUV4QkY3RC1pV01oRHpEVTNDN1lsOUpJSDVEdk5xMS00ZlM3aG54NGJxM3RQZWNPMkM1a2t4Yi04Qjc5Q0JiMEpDbEFHNEd6Y3lWa294Q3dfckN6NkxDa1VlZXBYWXo4UWJtZEtOdlVxN3JuYzZUSlZINzlfTzAzRFpHNUxkTjI3VnFtV1hhdmtidw?oc=5","date":"2024-11-18","type":"deal","source":"GlobeNewswire","summary":"Aclaris Therapeutics Announces Exclusive, Global License - GlobeNewswire","headline":"Aclaris Therapeutics Announces Exclusive, Global License","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE5xQS1LYlNJdjVqWXFnOGVPaFM4S2pONGNyZF94MEFXV1NTQ1E3Z0pVTTlpNDVJbEwxeW1lbTJ0dWNpLUJzWVpTak1Ga1FSbHBzczJyZkVJcFM4b3hkYVUyd09CMA?oc=5","date":"2024-01-30","type":"pipeline","source":"VISTA.Today","summary":"Chesterbrook's Aclaris Therapeutics Parts Ways with CEO, Initiates Strategic Review Following Setbacks - VISTA.Today","headline":"Chesterbrook's Aclaris Therapeutics Parts Ways with CEO, Initiates Strategic Review Following Setbacks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5NMUpyRFE1UTh6RTFFSHRoWEp0eUFsaUJVWGFrMGhobHJrVmhLMEYyb09oa0ppSDZ0Qm9PQlZfUmdKNkNJQV9jOUZ6dG1mZ2Y3MnQ1ZXZfcHdnZ2Ffa01sM29pel9xVFBxcjVvTGlOVW9IZ0pqS0pzbHhB?oc=5","date":"2023-05-18","type":"earnings","source":"Investopedia","summary":"Top Pharmaceutical Stocks for Q2 2023 - Investopedia","headline":"Top Pharmaceutical Stocks for Q2 2023","sentiment":"neutral"}],"patents":[],"drugCount":14,"phaseCounts":{"phase_1":3,"phase_2":9,"marketed":1,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}